| CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA NCT07558434 Peking Union Medical College Hospital | Not yet recruiting | Phase 2 | Apr 2026 |
| Romiplostim for Oral TPO-RA Resistant ITP NCT07612319 The First Affiliated Hospital of Soochow University | Recruiting | N/A | March 15, 2026 |
| Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA NCT07400341 The First Affiliated Hospital of Soochow University | Recruiting | Phase 2 | January 31, 2026 |
| A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia NCT07345000 Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | Phase 3 | Jan 2026 |
| Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients NCT07043894 Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | Phase 2 | December 25, 2025 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors NCT07586826 Peking University People's Hospital | Recruiting | Phase 2 | December 22, 2025 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors NCT07586813 Peking University People's Hospital | Recruiting | Phase 2 | December 22, 2025 |
| Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children NCT07214025 Assiut University | Not yet recruiting | — | November 1, 2025 |
| Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients NCT07162519 Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | N/A | September 20, 2025 |
| Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors NCT07128576 Zhujiang Hospital | Not yet recruiting | Phase 2 | September 15, 2025 |
| Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia NCT07206823 The First Affiliated Hospital of Soochow University | Recruiting | N/A | September 1, 2025 |
| A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors NCT07185893 Jun wang | Not yet recruiting | N/A | Sep 2025 |
| Romiplostim N01 for Chemotherapy-induced Thrombocytopenia NCT07063225 Institute of Hematology & Blood Diseases Hospital, China | Recruiting | Phase 2 | Aug 2025 |
| Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia NCT06898983 Anhui Provincial Hospital | Recruiting | Phase 2 | July 14, 2025 |
| Romiplostim N01 for Platelet Recovery After Haploidentical HSCT NCT07321626 First Affiliated Hospital of Zhejiang University | Recruiting | Phase 1 | June 1, 2025 |
| Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial NCT06992128 Institute of Hematology & Blood Diseases Hospital, China | Recruiting | Phase 2 | May 22, 2025 |
| A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 NCT06759636 The First Affiliated Hospital with Nanjing Medical University | Recruiting | Phase 3 | February 24, 2025 |
| Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT NCT06693791 Anhui Provincial Hospital | Recruiting | Phase 2 | December 1, 2024 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly NCT06345495 M.D. Anderson Cancer Center | Recruiting | Phase 2 | October 1, 2024 |
| Single Arm Romiplostim to Prevent CIT NCT07048249 Children's Hospital Medical Center, Cincinnati | Recruiting | Early phase 1 | January 26, 2024 |
| Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura NCT06137105 Assiut University | Not yet recruiting | — | December 1, 2023 |
| Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia NCT06497036 Geropharm | Active, not recruiting | Phase 3 | April 4, 2023 |
| Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia NCT05325593 Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Active, not recruiting | Phase 3 | December 2, 2022 |
| Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia NCT04870346 Kyowa Kirin Co., Ltd. | Active, not recruiting | — | May 10, 2021 |
| Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer NCT03937154 Amgen | Active, not recruiting | Phase 3 | February 26, 2020 |
| CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA NCT07523009 Peking Union Medical College Hospital | Withdrawn | Phase 2 | Jun 2026 |
| Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA NCT07532408 Peking Union Medical College Hospital | Withdrawn | Phase 2 | Jun 2026 |
| UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia NCT07001254 Anjali Sharathkumar | Withdrawn | Phase 2 | April 10, 2025 |
| Retrospective Study of Romiplostim for Platelet Engraftment After Allo-HSCT NCT07747246 Tongji Hospital | Completed | — | January 1, 2025 |
| Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP NCT06686927 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown status | Phase 2 | November 20, 2024 |
| Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia NCT06613880 Institute of Hematology & Blood Diseases Hospital, China | Unknown status | Phase 2 | October 24, 2024 |
| Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCT NCT07003256 Haikou Affiliated Hospital of Central South University Xiangya School of Medicine | Completed | — | September 1, 2024 |
| A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA NCT06535685 Peking Union Medical College Hospital | Unknown status | Phase 4 | August 2, 2024 |
| Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study NCT06516484 Peking Union Medical College Hospital | Unknown status | Phase 4 | July 30, 2024 |
| A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin NCT06440824 Shandong University | Unknown status | Phase 3 | June 1, 2024 |
| A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP NCT06658834 Institute of Hematology & Blood Diseases Hospital, China | Unknown status | Phase 2 | June 1, 2024 |
| Romiplostim in Chemotherapy-Induced Thrombocytopenia NCT06201663 Ain Shams University | Unknown status | Phase 3 | December 17, 2023 |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy NCT05323617 Amgen | Withdrawn | Phase 2 | August 31, 2023 |
| Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA NCT06009497 Peking Union Medical College Hospital | Unknown status | Phase 4 | Aug 2023 |
| Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe NCT06408324 European Research Consortium on ITP | Completed | — | November 24, 2022 |